With this approval, the drug can be used as monotherapy in people who start treatment for the first time or convert from other antiepileptic drugs (AEDs) to Aptiom.
Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove LDL-C or bad cholesterol from
With the completion of the deal, Perrigo now has rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. The deal also includes Novartis’s
Derived from the cell wall fractionation of non-pathogenic bacteria, MCNA is a biologic therapy developed to provide high risk non-muscle invasive bladder cancer patients who are refractory to
According to the company, MRX-I is claimed to offer physicians and patients a safer and better tolerated therapeutic option compared to the currently available oxazolidinone agents. MicuRx Pharmaceuticals
QIMR is focused on research of cancer, infectious diseases, mental health and a range of complex disorders. As part of the deal, BMS will be solely responsible for
As part of the deal, R-Tech Ueno will receive $54m in cash and 2.5 million Sucampo shares and Sucampo will buy 56% of the outstanding shares of R-Tech
The new R&D centre is part of the company’s global expansion plans to invest BRL20m ($5.6m) in equipment, facilities and technical staff. Initially, 20 specialized professionals will work
The proprietary synthetic molecules called Antibody Recruiting Molecules (ARMs) are developed by professor David Spiegel and his team at Yale University. The ARMs work by harnessing the power
Portage holds 54% equity interest in Biohaven, which filed an investigational drug application (IND) regarding BHV-0223 and recently secured approval from the US Food and Drug Administration (FDA)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.